Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03481660 KITE (CRTH258B2302) Diabetic eye disease Phase 3 356 Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q3-2020 (actual); Final: H2-2021 Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 NCT03917472 KINGFISHER (CRTH258B2305) Diabetic macular edema Phase 3 500 Change in best-corrected visual acuity (BCVA) from baseline up to week 52 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with visual impairment due to diabetic macular edema H2-2021 TBC 120 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation